Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer

2017222 citationsJournal Article

Authors

Good health and well-being

Published in: European Journal of Pharmaceutical Sciences

Volume 110, pp. 51-61

Field-Weighted Citation Impact: 6.02